Drug intelligence / Profile preview

ZoDerm Redi-Pads

Development stage: Discontinued
Lead developer: Fougera Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

**ZoDerm Redi-Pads** is a discontinued prescription topical medicated-pad formulation for **acne vulgaris** containing benzoyl peroxide and urea. Benzoyl peroxide provides antibacterial, oxidizing, comedolytic, and keratolytic activity, reducing acne-associated *Cutibacterium acnes* and promoting desquamation within follicles. Urea contributes humectant and keratolytic effects that soften the stratum corneum and support delivery in a moisturizing topical base. The product was developed and marketed by Bradley Pharmaceuticals through its dermatology business and was applied to affected skin after cleansing.

Brand names: ZoDerm Redi-Pads
Other names: benzoyl peroxide + ureabenzoyl peroxide/urea topical

Beyond the preview

Go deeper on ZoDerm Redi-Pads.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZoDerm Redi-Pads.

Explore the full profile